These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1351957)

  • 1. [Multicenter evaluation of a new local antihistaminic drug (levocabastine)].
    Bischoff P; Gerber M
    Klin Monbl Augenheilkd; 1992 May; 200(5):354-7. PubMed ID: 1351957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis.
    Giede C; Metzenauer P; Petzold U; Ellers-Lenz B
    Curr Med Res Opin; 2000; 16(3):153-63. PubMed ID: 11191004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antazoline/tetryzoline eyedrops in comparison with levocabastine eyedrops in acute allergic conjunctivitis].
    Wertheimer R; Blessmann G
    Klin Monbl Augenheilkd; 1997 Feb; 210(2):93-6. PubMed ID: 9229602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levocabastine: a new topical approach for the treatment of paediatric allergic rhinoconjunctivitis.
    Janssens MM
    Rhinol Suppl; 1992 Sep; 13():39-49. PubMed ID: 1358140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Levocabastine--a new antihistaminic for local treatment].
    Larsen BB; Pedersen B; Dahl R
    Ugeskr Laeger; 1993 Jun; 155(26):2070-3. PubMed ID: 8101023
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis.
    Verin P; Easty DL; Secchi A; Ciprandi G; Partouche P; Nemeth-Wasmer G; Brancato R; Harrisberg CJ; Estivin-Ebrardt C; Coster DJ; Apel AJ; Coroneo MT; Knorr M; Carmichael TR; Kent-Smith BT; Abrantes P; Leonardi A; Cerqueti PM; Modorati G; Martinez M
    Am J Ophthalmol; 2001 Jun; 131(6):691-8. PubMed ID: 11384563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
    Abelson MB; Greiner JV
    Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of topical levocabastine compared with oral terfenadine.
    Bahmer FA; Ruprecht KW
    Ann Allergy; 1994 May; 72(5):429-34. PubMed ID: 7909999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ophthalmic levocabastine for allergic conjunctivitis.
    Med Lett Drugs Ther; 1994 Apr; 36(920):35-6. PubMed ID: 7908401
    [No Abstract]   [Full Text] [Related]  

  • 10. [An open and controlled study of effectiveness and tolerance of Livostin eyedrops].
    Stara J; Krásný J; Plísková S; Síblová O
    Cesk Slov Oftalmol; 1997 Feb; 53(1):46-8. PubMed ID: 9213524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability of levocabastine eye drops.
    Janssens M; Blockhuys S
    Doc Ophthalmol; 1993; 84(2):111-8. PubMed ID: 7905376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of a combined therapy with a histamine H1 antagonist and a chemical mediator release inhibitor on allergic conjunctivitis.
    Fujishima H; Fukagawa K; Tanaka M; Uchio E; Takamura E; Nakagawa Y; Miyazaki D; Fukushima A; Okamoto S; Yokoi N
    Ophthalmologica; 2008; 222(4):232-9. PubMed ID: 18463425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Allergodil eye drops in the treatment of allergic conjunctivitis].
    Haicl P; Cerná H
    Cesk Slov Oftalmol; 2002 Jul; 58(4):254-8. PubMed ID: 12181881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects levocabastine ophthalmic solution (H1 receptor antagonist) on symptoms of vernal conjunctivitis. A prospective, randomized double-blind study].
    Graue E
    Gac Med Mex; 1994; 130(6):481-6. PubMed ID: 7557064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The early efficacy of topical levocabastine in patients with allergic conjunctivitis.
    Fujishima H; Fukagawa K; Takano Y; Okamoto S; Nakagawa Y; Uchio E; Yokoi N; Fukushima A; Takamura E
    Allergol Int; 2006 Sep; 55(3):301-3. PubMed ID: 17075271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Safety and efficacy of a new preservative-free levocabastine ophthalmic solution (Levofree®) using the conjunctival provocation test].
    Allaire C; Siou-Mermet R; Bassols A
    J Fr Ophtalmol; 2012 Sep; 35(7):491-8. PubMed ID: 22498504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emedastine and allergic conjunctivitis: new preparation. Poor assessment.
    Prescrire Int; 2001 Apr; 10(52):39-40. PubMed ID: 11718155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid onset of action of levocabastine eye-drops in histamine-induced conjunctivitis.
    Stokes TC; Feinberg G
    Clin Exp Allergy; 1993 Sep; 23(9):791-4. PubMed ID: 10779311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onset of action, effectiveness and tolerance of levocabastine and nedocromil in topical therapy of seasonal allergic rhinoconjunctivitis. The Deutsche Rhinitis-Studiengruppe.
    Kremer B; Tündermann A; Goldschmidt O
    Arzneimittelforschung; 1998 Sep; 48(9):924-30. PubMed ID: 9793620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.